Neil Parrott
Neil Parrott
Modeling and simulation scientist, F. Hoffmann-LaRoche
Verified email at
TitleCited byYear
A novel strategy for physiologically based predictions of human pharmacokinetics
HM Jones, N Parrott, K Jorga, T Lavé
Clinical pharmacokinetics 45 (5), 511-542, 2006
A novel strategy for physiologically based predictions of human pharmacokinetics
HM Jones, N Parrott, K Jorga, T Lavé
Clinical pharmacokinetics 45 (5), 511-542, 2006
Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective
HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, ...
Clinical Pharmacology & Therapeutics 97 (3), 247-262, 2015
Prediction of intestinal absorption: comparative assessment of gastroplus™ and idea™
N Parrott, T Lavé
European journal of pharmaceutical sciences 17 (1-2), 51-61, 2002
Predicting pharmacokinetics of drugs using physiologically based modeling—application to food effects
N Parrott, V Lukacova, G Fraczkiewicz, MB Bolger
The AAPS journal 11 (1), 45-53, 2009
Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling
HM Jones, N Parrott, G Ohlenbusch, T Lavé
Clinical pharmacokinetics 45 (12), 1213-1226, 2006
A strategy for preclinical formulation development using GastroPlus™ as pharmacokinetic simulation tool and a statistical screening design applied to a dog study
M Kuentz, S Nick, N Parrott, D Röthlisberger
European journal of pharmaceutical sciences 27 (1), 91-99, 2006
Applications of physiologically based absorption models in drug discovery and development
N Parrott, T Lave
Molecular pharmaceutics 5 (5), 760-775, 2008
An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery
N Parrott, N Paquereau, P Coassolo, T Lavé
Journal of pharmaceutical sciences 94 (10), 2327-2343, 2005
Challenges and opportunities with modelling and simulation in drug discovery and drug development
T Lavé, N Parrott, HP Grimm, A Fleury, M Reddy
Xenobiotica 37 (10-11), 1295-1310, 2007
Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man
N Parrott, H Jones, N Paquereau, T Lavé
Basic & clinical pharmacology & toxicology 96 (3), 193-199, 2005
CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor
L Lindemann, G Jaeschke, A Michalon, E Vieira, M Honer, W Spooren, ...
Journal of Pharmacology and Experimental Therapeutics 339 (2), 474-486, 2011
Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants
N Parrott, B Davies, G Hoffmann, A Koerner, T Lave, E Prinssen, ...
Clinical pharmacokinetics 50 (9), 613-623, 2011
A fast virtual screening filter for cytochrome P450 3A4 inhibition liability of compound libraries
J Zuegge, U Fechner, O Roche, NJ Parrott, O Engkvist, G Schneider
Quantitative Structure‐Activity Relationships 21 (3), 249-256, 2002
Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression
L Lindemann, RH Porter, SH Scharf, B Kuennecke, A Bruns, ...
Journal of Pharmacology and Experimental Therapeutics 353 (1), 213-233, 2015
Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis
D Tam, H Sun, KS Pang
Drug metabolism and disposition 31 (10), 1214-1226, 2003
A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation
C Suenderhauf, N Parrott
Pharmaceutical research 30 (1), 1-15, 2013
Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates–an evaluation and case study using GastroPlus™
AT Heikkinen, G Baneyx, A Caruso, N Parrott
European journal of pharmaceutical sciences 47 (2), 375-386, 2012
Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state
M Arndt, H Chokshi, K Tang, NJ Parrott, C Reppas, JB Dressman
European Journal of Pharmaceutics and Biopharmaceutics 84 (3), 633-641, 2013
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration
G Baneyx, N Parrott, C Meille, A Iliadis, T Lavé
European Journal of Pharmaceutical Sciences 56, 1-15, 2014
The system can't perform the operation now. Try again later.
Articles 1–20